BACKGROUND AND PURPOSE: The construct of vascular cognitive impairment (VCI) includes many whose care is or will be costly. Nevertheless, estimates of these costs are not well described. We therefore set out to estimate the societal costs of VCI in elderly people. METHODS: In a secondary analysis of the Canadian Study of Health and Aging, a representative cohort study, Canadian dollar costs using a societal perspective were estimated by standard methods. RESULTS: The total annual per-patient societal costs for VCI by severity were $15 022 for those with mild disease, $14 468 for those with mild to moderate disease, $20 063 for those with moderate disease, and $34 515 for those with severe disease. The most expensive component per individual was the cost of institutional long-term care. Although severe impairment was associated with higher costs, the extent of institutionalization at all levels of severity and less drug use among those more severely impaired mitigated a severity-cost gradient. CONCLUSIONS: The societal costs of VCI are not inconsiderable. In contrast to Alzheimer disease, there is no clear gradient relating cost to severity. Unpaid caregiver costs are an important aspect of societal costs, even in those with only mild impairment.
BACKGROUND AND PURPOSE: The construct of vascular cognitive impairment (VCI) includes many whose care is or will be costly. Nevertheless, estimates of these costs are not well described. We therefore set out to estimate the societal costs of VCI in elderly people. METHODS: In a secondary analysis of the Canadian Study of Health and Aging, a representative cohort study, Canadian dollar costs using a societal perspective were estimated by standard methods. RESULTS: The total annual per-patient societal costs for VCI by severity were $15 022 for those with mild disease, $14 468 for those with mild to moderate disease, $20 063 for those with moderate disease, and $34 515 for those with severe disease. The most expensive component per individual was the cost of institutional long-term care. Although severe impairment was associated with higher costs, the extent of institutionalization at all levels of severity and less drug use among those more severely impaired mitigated a severity-cost gradient. CONCLUSIONS: The societal costs of VCI are not inconsiderable. In contrast to Alzheimer disease, there is no clear gradient relating cost to severity. Unpaid caregiver costs are an important aspect of societal costs, even in those with only mild impairment.
Authors: Deborah A Levine; Andrzej T Galecki; Kenneth M Langa; Frederick W Unverzagt; Mohammed U Kabeto; Bruno Giordani; Virginia G Wadley Journal: JAMA Date: 2015-07-07 Impact factor: 56.272
Authors: A Morandi; P Pandharipande; M Trabucchi; R Rozzini; G Mistraletti; A C Trompeo; C Gregoretti; L Gattinoni; M V Ranieri; L Brochard; D Annane; C Putensen; U Guenther; P Fuentes; E Tobar; A R Anzueto; A Esteban; Y Skrobik; J I F Salluh; M Soares; C Granja; A Stubhaug; S E de Rooij; E Wesley Ely Journal: Intensive Care Med Date: 2008-06-18 Impact factor: 17.440
Authors: David W Zhou; M Brandon Westover; Lauren M McClain; Sunil B Nagaraj; Ednan K Bajwa; Sadeq A Quraishi; Oluwaseun Akeju; J Perren Cobb; Patrick L Purdon Journal: Conf Proc IEEE Eng Med Biol Soc Date: 2015
Authors: P P Pandharipande; T D Girard; J C Jackson; A Morandi; J L Thompson; B T Pun; N E Brummel; C G Hughes; E E Vasilevskis; A K Shintani; K G Moons; S K Geevarghese; A Canonico; R O Hopkins; G R Bernard; R S Dittus; E W Ely Journal: N Engl J Med Date: 2013-10-03 Impact factor: 91.245
Authors: Jessica A Palakshappa; Kathryn E Callahan; Nicholas M Pajewski; Daniel Clark Files; James J Willard; Jeff D Williamson Journal: Ann Am Thorac Soc Date: 2021-10